-
In Hollywood, AI's no match for creativity, say top executives
-
Sao Paulo AI policing nabs criminals, and a few innocents
-
Trump faces coalition of the unwilling on Iran
-
Nvidia chief expects revenue of $1 trillion through 2027
-
Nvidia making AI module for outer space
-
Migrant workers bear brunt of Iran attacks in Gulf
-
Former tennis world number 39 banned for doping
-
Kennedy Center board approves 2-year closure for renovation
-
US judge halts implementation of Trump vaccine overhaul
-
Afghanistan accuses Pakistan of deadly airstrike on drug rehab centre in Kabul
-
Iran footballers train with Australia club and say 'everything will be fine'
-
Trump asks China to delay Xi summit as Iran war rages
-
Multiple suicide bombers hit Nigeria's Maiduguri city after years of calm
-
Wolves fightback frustrates Brentford
-
Israel president says Europe should back fight against Hezbollah as troops operate in Lebanon
-
Israel president tells AFP Europe should back efforts to 'eradicate' Hezbollah
-
Equities rise on oil easing, with focus on Iran war and central banks
-
Mbappe set for Real Madrid return against Man City
-
Nvidia rides 'claw' craze with AI agent platform
-
Alleged narco trafficker makes first US court appearance
-
Neymar misses out as Endrick returns to Brazil squad
-
Afghanistan accuses Pakistan of killing civilians in Kabul strike
-
South Lebanon's Christian towns insist they are not part of Israel-Hezbollah war
-
Alleged narco trafficker Marset makes first US court appearance
-
Securing the Strait of Hormuz: Tactics and threats
-
Cuba hit by total blackout as US fuel blockade bites
-
'Buffy' reboot cancelled: Sarah Michelle Gellar
-
PSG will go for the kill against Chelsea: Dembele
-
Afghan govt accuses Pakistan after new strikes on Kabul
-
Chelsea huddle not meant to 'antagonise' says Rosenior
-
Talks towards international panel to tackle 'inequality emergency' begin at UN
-
Trump pushes for 'enthusiasm' from allies to secure Hormuz
-
US, China hold 'constructive' talks on trade, but Trump visit in doubt
-
Laporta's new Barca chapter begins with Newcastle clash
-
EU talks energy as oil price soars
-
Out-of-favour Livingstone says 'no-one cares' in England set-up
-
Rising star Antonelli says Chinese GP triumph 'starting point' for F1 success
-
Stagflation risk in US 'quite high': Nobel-winning economist Stiglitz
-
Israel army says ground assault against Hezbollah underway in Lebanon
-
Swiss government rejects proposal to limit immigration
-
Ingredients of life discovered in Ryugu asteroid samples
-
Why Iranian drones are hard to stop
-
Teen star Dowman ready to make impact for Arsenal says Arteta
-
Jones says England would be 'foolhardy' to sack Borthwick before Rugby World Cup
-
Man City must be 'perfect' to stun Real Madrid: Guardiola
-
Ntamack set for Toulouse return at Bordeaux-Begles
-
Hours-long fuel queues in Laos capital Vientiane
-
France threatens to block funds for India over climate inaction
-
Will Yemen's Houthis join the Mideast war?
-
Oscar winner Sean Penn skips ceremony to visit Kyiv
Trump announces Pfizer deal he says will lower certain drug prices
The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.
President Donald Trump, flanked by top health officials, was scant on details regarding what or how many drugs were included in the agreement, the announcement of which came as Washington faced a looming government shutdown.
Under the deal Pfizer is to charge "Most Favored Nation" pricing -- matching the lowest price offered in other wealthy nations -- to Medicaid, the US health insurance program for low-income Americans.
The White House also said it would unveil a website -- called TrumpRx -- that would allow consumers to directly purchase some medications from manufacturers at discounted rates.
Like Trump, Pfizer CEO Albert Bourla heralded the deal as a great achievement, although a statement from the company was equally vague on specifics.
The company did say a "large majority" of "primary care treatments and some select specialty brands" could be offered at savings from 50 percent to 85 percent.
"We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry's valuations to historic lows," said Bourla.
Part of the deal included Pfizer agreeing to "invest $70 billion to reshore domestic manufacturing facilities" to the United States.
- Wider impact unclear -
Trump's initiative revives drug-pricing efforts from his first term. The president has taken steps since returning to the White House to pressure pharmaceutical companies into voluntarily lowering their prices.
In July the US leader sent letters to leading pharmaceutical companies demanding they lower drug prices.
Democrats have long indicated that they, too, would like to lower drug prices.
In a report released Monday, independent Senator Bernie Sanders said that Trump's efforts on the issue had "made headlines" but had done "little beyond that."
The member of the Senate's health committee said in his report that since Trump sent the letters over the summer, the prices of 87 drugs actually increased.
Drug costs for consumers in the United States can depend on several variables, notably insurance coverage.
Many people receive insurance through an employer, the health insurance market or government programs including Medicare, which is for seniors, and the safety net Medicaid.
It is not clear how Tuesday's deal will impact drug pricing in the commercial insurance market.
The announcement comes as drugmakers gird for a 100-percent tariff Trump said he would impose on branded pharmaceutical products entering the country from October 1 -- unless companies were building manufacturing plants in the United States.
But details surrounding the rollout remain unclear.
Since returning to the presidency in January, Trump has imposed sector-specific tariffs on imports like steel, aluminum and autos, while launching investigations into other areas like pharmaceuticals that could lead to new levies.
Asked Tuesday about the timeline for fresh tariffs, Commerce Secretary Howard Lutnick said the Trump administration plans to allow negotiations with companies to play out.
A.Ammann--VB